Výsledky vyhľadávania - "nirsevimab"

Transamniotic fetal delivery of recombinant human immunoglobulin monoclonal antibodies: A potential novel strategy for prevention of neonatal respiratory syncytial virus (RSV) disease Autor Huang, Alex L., Scire, Emily M., Dang, Tanya T., Tai, Melody, Zacharakis, Eva, Yohannes, Blen, Kycia, Ina, Zurakowski, David, Fauza, Dario O.

“…Modified monoclonal class-G immunoglobulins (IgG) have been shown to protect infants from respiratory syncytial virus (RSV), a prevalent disease with…”
Získať plný text

Acceptance and safety of the RSV-preventive treatment of newborns with nirsevimab in the maternity department: a prospective longitudinal cohort study in FranceResearch in context Autor Charlotte Ocana de Sentuary, Clara Testard, Marion Lagrée, Maxime Leroy, Lisa Gasnier, Alicia Enes-Dias, Constance Leruste, Diariatou Diallo, Michael Génin, Thameur Rakza, François Dubos

“…Background: To evaluate the acceptance and safety of the treatment of newborns with nirsevimab (a long-acting monoclonal antibody designed to prevent…”
Získať plný text

Prevention of respiratory syncytial virus infection in children. Recommendations of the Polish Society of Paediatrics and the National Paediatric Consultant Autor Jackowska, Teresa, Wrotek, August, Beń-Skowronek, Iwona, Dembiński, Łukasz, Jarmoliński, Tomasz, Mazur, Artur, Medyńska, Anna, Plata-Nazar, Katarzyna, Styczyński, Jan, Szczepański, Tomasz, Toporowska-Kowalska, Ewa, Hartmann, Piotr, Czajka, Hanna, Peregud-Pogorzelski, Jarosław

“…Respiratory syncytial virus (RSV) is one of the most important etiological agents of acute lower respiratory tract infections in children (LRTI-RSV). RSV…”
Získať plný text

Changes in RSV-associated lower respiratory tract infections among hospitalized and outpatient children under 2 years in Northern Bavaria after general recommendation of Nirsevimab immunization in 2024 Autor Zhou, Ying, Hecker, Katharina, Engels, Géraldine, Andres, Oliver, Knies, Kerstin, Krempl, Christine, Weissbrich, Benedikt, Härtel, Christoph, Streng, Andrea, Liese, Johannes

“…This study investigated changes in the incidence and age distribution of RSV-associated lower respiratory tract infections (RSV-LRTI) among children in…”
Získať plný text

RSV Prevention in All Infants: Which Is the Most Preferable Strategy? Autor Esposito, Susanna, Abu Raya, Bahaa, Baraldi, Eugenio, Flanagan, Katie, Martinon Torres, Federico, Tsolia, Maria, Zielen, Stefan

“…Respiratory syncytial virus (RSV) causes a spectrum of respiratory illnesses in infants and young children that may lead to hospitalizations and a substantial…”
Získať plný text

Impact of nirsevimab on admission to a Spanish pediatric intensive care unit because of RSV bronchiolitis: Unicentric observational study from 2017 to 2024 Autor Espeleta‐Fox, Ana, García‐Salido, Alberto, Vallespín‐Casas, Almudena, Leoz‐Gordillo, Inés, Unzueta‐Roch, José Luis, De Lama Caro‐Patón, Gema, García‐Teresa, María Ángeles, Martínez de Azagra‐Garde, Amelia

Získať plný text

Long-term impact of nirsevimab on prevention of respiratory syncytial virus infection using a real-world global database Autor Kitano, Taito, Tsuzuki, Shinya, Fukuda, Haruhisa, Yoshida, Sayaka

“…The preventive effect of nirsevimab, a long-acting monoclonal antibody, on infants with respiratory syncytial virus (RSV) infection beyond six months has…”
Získať plný text

Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model Autor Kieffer, Alexia, Beuvelet, Matthieu, Sardesai, Aditya, Musci, Robert, Milev, Sandra, Roiz, Julie, Lee, Jason K H

“…Abstract Background Respiratory syncytial virus (RSV) is associated with substantial morbidity in the United States, especially among infants. Nirsevimab, an…”
Získať plný text

High Uptake of Respiratory Syncitial Virus Prevention for Neonates in a Military Treatment Facility Autor Homo, Richelle L., Groberg, Andrew, Donahue, Megan, Halverson, Dustin, Wooten, Anna, Ponnapakkam, Adharsh

“…We investigated the uptake of nirsevimab for infants and the bivalent respiratory syncytial virus prefusion F (RSVPreF) vaccine for pregnant persons as…”
Získať plný text

Factors Influencing Parental Decisions on Respiratory Syncytial Virus Immunoprophylaxis Autor Shedlock, Katherine E., Hicks, Steven D., Gardner, Ruth E., Kaye, Leah D., Lipsett, Brody J., Schaefer, Eric W., Paul, Ian M., Fogel, Benjamin N.

“…New respiratory syncytial virus (RSV) immunizations for infants and pregnant mothers recently became available to prevent severe RSV disease in infants. We…”
Získať plný text

Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting monoclonal antibodies, Galicia, Spain, September and October 2023 Autor Martinón-Torres, Federico, Mirás-Carballal, Susana, Durán-Parrondo, Carmen

“…A monoclonal antibody for universal respiratory syncytial virus prophylaxis in infants has recently been licensed. We share our experiences of integrating…”
Získať plný text

Effectiveness of nirsevimab among infants in their first RSV season in the United States, October 2023–March 2024: a test-negative design analysisResearch in context Autor Amanda B. Payne, Steph Battan-Wraith, Elizabeth A.K. Rowley, Melissa S. Stockwell, Sara Y. Tartof, Kristin Dascomb, Stephanie A. Irving, Brian Dixon, Sarah W. Ball, Mark W. Tenforde, Gabriela Vazquez-Benitez, Ashley B. Stephens, Jungmi Han, Karthik Natarajan, S. Bianca Salas, Cassandra Bezi, Lina S. Sy, Bruno Lewin, Tamara Sheffield, Julie Arndorfer, Daniel Bride, Josh Van Otterloo, Allison L. Naleway, Padma D. Koppolu, Shaun Grannis, William Fadel, Colin Rogerson, Tom Duszynski, Sarah E. Reese, Patrick K. Mitchell, Sean Chickery, Heidi L. Moline, Morgan Najdowski, Allison Avrich Ciesla, Emily L. Reeves, Malini DeSilva, Katherine E. Fleming-Dutra, Ruth Link-Gelles

“…Background: In August 2023, the Centers for Disease Control and Prevention recommended nirsevimab, a long-acting monoclonal antibody, for all U.S. infants aged…”
Získať plný text

ACTIVE POST-MARKETING SAFETY SURVEILLANCE OF NIRSEVIMAB ADMINISTERED TO CHILDREN IN WESTERN AUSTRALIA, APRIL-JULY 2024 Autor Carcione, Dale, Spencer, Phoebe, Pettigrew, Grace, Leeb, Alan, Drake-Brockman, Carla, Ford, Timothy, Effler, Paul

“…Children receiving nirsevimab were texted a link to an online survey to monitor adverse events following immunization. Total of 4340 parents received the link,…”
Zistit podrobnosti o prístupe

Who is at risk of a respiratory syncytial virus hospitalisation? A linked, population-based birth cohort analysis in children aged less than 5 yearsResearch in context Autor Mohinder Sarna, Christopher C. Blyth, Belaynew W. Taye, Huong Le, Peter Richmond, Kathryn Glass, Avram Levy, Cara Minney-Smith, Daniel Oakes, Jeffrey Cannon, Melinda France, Hannah C. Moore

“…Background: Respiratory syncytial virus (RSV) is a major cause of acute lower respiratory infections globally in children under five years. With the…”
Získať plný text

Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study Autor Shoukat, Affan, Abdollahi, Elaheh, Galvani, Alison P., Halperin, Scott A., Langley, Joanne M., Moghadas, Seyed M.

“…The cost-effectiveness of immunisation strategies with a long-acting monoclonal antibody (nirsevimab) and/or a protein-based maternal vaccine (RSVpreF) for…”
Získať plný text

Vaccination strategies for patients under monoclonal antibody and other biological treatments: an updated comprehensive review based on EMA authorisations to January 2024 Autor Rivera-Izquierdo, Mario, Morales-Portillo, Arturo, Guerrero-Fernández de Alba, Inmaculada, Fernández-Martínez, Nicolás Francisco, Schoenenberger-Arnaiz, Joan Antoni, Barranco-Quintana, José Luis, Valero-Ubierna, Carmen

“…Monoclonal antibodies (mAbs) and other biological agents are being increasingly approved in the last years with very different indications. Their highly…”
Získať plný text

Efficacy of nirsevimab for the prevention of RSV disease in infants: A systematic review, meta-analysis of randomized controlled trials, and global perspectives on recommendations and unmet needs Autor Lien, Hsin-Chweng, Lien, Chi-Hone, Liu, Tzu-Yu, Weng, Shun-Long, Tai, Yu-Lin, Huang, Ya-Ning, Chi, Hsin, Chiu, Nan-Chang, Yeung, Chun-Yan, Lin, Chien-Yu

“…Respiratory syncytial virus (RSV) is a major cause of infant hospitalizations, with limited prophylactic options historically available. Nirsevimab, a…”
Získať plný text

Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection Autor Brady, Tyler, Cayatte, Corinne, Roe, Tiffany L., Speer, Scott D., Ji, Hong, Machiesky, LeeAnn, Zhang, Tianhui, Wilkins, Deidre, Tuffy, Kevin M., Kelly, Elizabeth J.

“…Nirsevimab is an extended half-life (M252Y/S254T/T256E [YTE]-modified) monoclonal antibody to the pre-fusion conformation of the respiratory syncytial virus…”
Získať plný text

RS virus vaccine Autor Kurasawa, Kentaro

“…RS virus infection is an important disease in infants and young children, but there is no effective prevention or treatment, and treatment is mainly…”
Získať plný text

RSウイルスワクチン Autor 倉澤, 健太郎

“…RSウイルス感染症は乳幼児においては重要な疾患であるが，有効な予防や治療はなく，対症療法が中心となる．2000年以降はハイリスク児に対するモノクローナル抗…”
Získať plný text